Halstead SB, 2002. Dengue. Curr Opin Infect Dis 15: 471–476.
Guzman MG, Kouri G, 2008. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987–2007. Trans R Soc Trop Med Hyg 102: 522–523.
Rico-Hesse R, 2010. Dengue virus virulence and transmission determinants. Curr Top Microbiol Immunol 338: 45–55.
Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, Abeysinghe N, de-Silva AM, Gunasekera M, 2009. Severe dengue epidemics in Sri Lanka, 2003–2006. Emerg Infect Dis 15: 192–199.
Guzman MG, Sierra B, Kouri G, Farrar J, Simmons C, 2010. Host and virus determinants of susceptibility and dengue disease severity. Hanley KA, Weaver SC, eds. Frontiers in Dengue Virus Research. Norfolk, United Kingdom: Caister Academic Press, 79–102.
Rossi CA, Drabick JJ, Gambel JM, Sun W, Lewis TE, Henchal EA, 1998. Laboratory diagnosis of acute dengue fever during the United Nations Mission in Haiti, 1995–1996. Am J Trop Med Hyg 59: 275–278.
Trofa AF, DeFraites RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr, 1997. Dengue fever in US military personnel in Haiti. JAMA 277: 1546–1548.
Ventura AK, Ehrenkranz NJ, 1976. Endemic dengue virus infection in Hispaniola. I. Haiti. J Infect Dis 134: 436–441.
Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, Kanesa-Thasan N, Hayes CG, Watts DM, 2001. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 65: 180–183.
de la C Sierra B, Kourí G, Guzmán MG, 2007. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 152: 533–542.
WHO Statistical Information System (WHOSIS), 2006. Probability of Dying Aged < 5 Years per 1000 Live Births (Under-Five Mortality Rate). Available at: http://www.who.int/whosis/indicators/2007MortChild/en/index.html. Accessed April 1, 2010.
Noel F, Wright PF, Bois G, Deschamps MM, de Matteis P, Cassangnol R, Thimothee M, Celestin K, Vaz L, Bradshaw JA, Brignoli E, Zhu Y, Johnson WD, Fitzgerald D, Pape JW, 2006. Contribution of bacterial sepsis to morbidity in infants born to HIV-infected Haitian mothers. J Acquir Immune Defic Syndr 43: 313–319.
Russell PK, Nisalak A, Sukhavachana P, Vivona S, 1967. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99: 285–290.
Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405–413.
Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC, 2009. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 81: 834–841.
Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825–833.
Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K, 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718–728.
Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA, 2009. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963–968.
Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, Lien le B, Quy NT, Hieu NT, Hien TT, McElnea C, Young P, Whitehead S, Hung NT, Farrar J, 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196: 416–424.
Noel F, Mehta S, Zhu Y, Rouzier Pde M, Marcelin A, Shi JR, Nolte C, Severe L, Deschamps MM, Fitzgerald DW, Johnson WD, Wright PF, Pape JW, 2008. Improving outcomes in infants of HIV-infected women in a developing country setting. PLoS ONE 3: e3723.
Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, Lien le B, Quy NT, Hieu NT, Hieu LT, Hien TT, Hung NT, Farrar J, Simmons CP, 2008. Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516–524.
Chaturvedi U, Nagar R, Shrivastava R, 2006. Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 47: 155–166.
Lenhart A, Orelus N, Maskill R, Alexander N, Streit T, McCall PJ, 2008. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 13: 56–67.
Pengsaa K, Limkittikul K, Luxemburger C, Yoksan S, Chambonneau L, Ariyasriwatana C, Lapphra K, Chanthavanich P, Lang J, Sabchareon A, 2008. Age-specific prevalence of dengue antibodies in Bangkok infants and children. Pediatr Infect Dis J 27: 461–463.
Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, Hammond SN, Nuñez A, Avilés W, Henn MR, Holmes EC, Gordon A, Coloma J, Kuan G, Harris E, 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 201: 5–14.
Anonymous, 1998. Asia: dengue fever, a man-made disease. The Economist 347 (8066): 538.
Bonnlander H, Rossignol AM, Rossignol PA, 1994. Malaria in central Haiti: a hospital-based retrospective study, 1982–1986 and 1988–1991. Bull Pan Am Health Organ 28: 9–16.
Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, Hammond SN, Nuñez A, Avilés W, Henn MR, Holmes EC, Gordon A, Coloma J, Kuan G, Harris E, 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 201: 5–14.
Kuan G, Gordon A, Avilés W, Ortega O, Hammond SN, Elizondo D, Nuñez A, Coloma J, Balmaseda A, Harris E, 2009. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol 170: 120–129.
Lenhart A, Orelus N, Maskill R, Alexander N, Streit T, McCall PJ. 2008. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 13: 56–67.
Climate Information for Haiti. Available at: http://www.climatetemp.info/haiti/.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1087 | 973 | 235 |
Full Text Views | 268 | 13 | 2 |
PDF Downloads | 83 | 14 | 2 |
Dengue is endemic to Haiti but not recognized as an important illness in the autochthonous population. To evaluate the prevalence of antibodies to dengue virus (DENV), serum samples from infants and young children 7–36 months of age (n = 166) were assayed by plaque reduction neutralization assays to each DENV serotype. Dengue virus serotype 1 had infected 40% of this study population, followed by serotype 2 (12%), serotype 3 (11%), and serotype 4 (2%). Fifty-three percent of infants and young children less than 12 months of age had already experienced DENV infection, and the seroprevalence of antibody to DENV increased to 65% by 36 months. Heterotypic antibody responses were an important component of the total dengue immunity profile.
Financial support: The study was supported by an Infectious Disease Society of America summer fellowship to Meghan Rioth, a supplement to the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet), and the Vanderbilt Emphasis Program.
Authors' addresses: Meghan Rioth, Vanderbilt University, Nashville, TN, E-mail: meghan.rioth@vanderbilt.edu. Carole Anne Beauharnais, Francine Noel, and Jean W. Pape, GHESKIO Centers, Port-au-Prince, E-mails: caroleanne26@hotmail.com, fsevere@gheskio.org, and jwpape@gheskio.org. Mine R. Ikizler, Pediatric Infectious Diseases, Nashville, TN, E-mail: mine.ikizler@vanderbilt.edu. Sapna Mehta, E-mail: mehta_sapna@hotmail.com. Yuwei Zhu, Department of Biostatistics, Vanderbilt University, Nashville, TN, E-mail: yuwei.zhu@vanderbilt.edu. Carole A. Long, Malaria Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, E-mail: clong@niaid.nih.gov. Peter F. Wright, Dartmouth Medical School, Lebanon, NH, E-mail: peter.f.wright@dartmouth.edu.
Halstead SB, 2002. Dengue. Curr Opin Infect Dis 15: 471–476.
Guzman MG, Kouri G, 2008. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987–2007. Trans R Soc Trop Med Hyg 102: 522–523.
Rico-Hesse R, 2010. Dengue virus virulence and transmission determinants. Curr Top Microbiol Immunol 338: 45–55.
Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, Abeysinghe N, de-Silva AM, Gunasekera M, 2009. Severe dengue epidemics in Sri Lanka, 2003–2006. Emerg Infect Dis 15: 192–199.
Guzman MG, Sierra B, Kouri G, Farrar J, Simmons C, 2010. Host and virus determinants of susceptibility and dengue disease severity. Hanley KA, Weaver SC, eds. Frontiers in Dengue Virus Research. Norfolk, United Kingdom: Caister Academic Press, 79–102.
Rossi CA, Drabick JJ, Gambel JM, Sun W, Lewis TE, Henchal EA, 1998. Laboratory diagnosis of acute dengue fever during the United Nations Mission in Haiti, 1995–1996. Am J Trop Med Hyg 59: 275–278.
Trofa AF, DeFraites RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr, 1997. Dengue fever in US military personnel in Haiti. JAMA 277: 1546–1548.
Ventura AK, Ehrenkranz NJ, 1976. Endemic dengue virus infection in Hispaniola. I. Haiti. J Infect Dis 134: 436–441.
Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, Kanesa-Thasan N, Hayes CG, Watts DM, 2001. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 65: 180–183.
de la C Sierra B, Kourí G, Guzmán MG, 2007. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 152: 533–542.
WHO Statistical Information System (WHOSIS), 2006. Probability of Dying Aged < 5 Years per 1000 Live Births (Under-Five Mortality Rate). Available at: http://www.who.int/whosis/indicators/2007MortChild/en/index.html. Accessed April 1, 2010.
Noel F, Wright PF, Bois G, Deschamps MM, de Matteis P, Cassangnol R, Thimothee M, Celestin K, Vaz L, Bradshaw JA, Brignoli E, Zhu Y, Johnson WD, Fitzgerald D, Pape JW, 2006. Contribution of bacterial sepsis to morbidity in infants born to HIV-infected Haitian mothers. J Acquir Immune Defic Syndr 43: 313–319.
Russell PK, Nisalak A, Sukhavachana P, Vivona S, 1967. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99: 285–290.
Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405–413.
Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC, 2009. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 81: 834–841.
Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP, 2009. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 81: 825–833.
Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K, 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718–728.
Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA, 2009. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963–968.
Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, Lien le B, Quy NT, Hieu NT, Hien TT, McElnea C, Young P, Whitehead S, Hung NT, Farrar J, 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196: 416–424.
Noel F, Mehta S, Zhu Y, Rouzier Pde M, Marcelin A, Shi JR, Nolte C, Severe L, Deschamps MM, Fitzgerald DW, Johnson WD, Wright PF, Pape JW, 2008. Improving outcomes in infants of HIV-infected women in a developing country setting. PLoS ONE 3: e3723.
Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, Lien le B, Quy NT, Hieu NT, Hieu LT, Hien TT, Hung NT, Farrar J, Simmons CP, 2008. Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516–524.
Chaturvedi U, Nagar R, Shrivastava R, 2006. Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 47: 155–166.
Lenhart A, Orelus N, Maskill R, Alexander N, Streit T, McCall PJ, 2008. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 13: 56–67.
Pengsaa K, Limkittikul K, Luxemburger C, Yoksan S, Chambonneau L, Ariyasriwatana C, Lapphra K, Chanthavanich P, Lang J, Sabchareon A, 2008. Age-specific prevalence of dengue antibodies in Bangkok infants and children. Pediatr Infect Dis J 27: 461–463.
Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, Hammond SN, Nuñez A, Avilés W, Henn MR, Holmes EC, Gordon A, Coloma J, Kuan G, Harris E, 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 201: 5–14.
Anonymous, 1998. Asia: dengue fever, a man-made disease. The Economist 347 (8066): 538.
Bonnlander H, Rossignol AM, Rossignol PA, 1994. Malaria in central Haiti: a hospital-based retrospective study, 1982–1986 and 1988–1991. Bull Pan Am Health Organ 28: 9–16.
Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborío S, Hammond SN, Nuñez A, Avilés W, Henn MR, Holmes EC, Gordon A, Coloma J, Kuan G, Harris E, 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 201: 5–14.
Kuan G, Gordon A, Avilés W, Ortega O, Hammond SN, Elizondo D, Nuñez A, Coloma J, Balmaseda A, Harris E, 2009. The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol 170: 120–129.
Lenhart A, Orelus N, Maskill R, Alexander N, Streit T, McCall PJ. 2008. Insecticide-treated bednets to control dengue vectors: preliminary evidence from a controlled trial in Haiti. Trop Med Int Health 13: 56–67.
Climate Information for Haiti. Available at: http://www.climatetemp.info/haiti/.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1087 | 973 | 235 |
Full Text Views | 268 | 13 | 2 |
PDF Downloads | 83 | 14 | 2 |